亲属
发表于 2025-3-26 22:15:50
http://reply.papertrans.cn/43/4204/420330/420330_31.png
Intuitive
发表于 2025-3-27 03:19:29
Challenging Proteostasis: Role of the Chaperone Network to Control Aggregation-Prone Proteins in Hume Proteostasis Network (PN) are molecular chaperones that serve widely in protein biogenesis under physiological conditions, and prevent protein misfolding and aggregation enhanced by conditions of cellular stress. For Alzheimer’s, Parkinson’s, Huntington’s diseases and ALS, multiple classes of mole
不要严酷
发表于 2025-3-27 09:16:45
http://reply.papertrans.cn/43/4204/420330/420330_33.png
确认
发表于 2025-3-27 10:26:32
Chaperome Networks – Redundancy and Implications for Cancer Treatment organisms have paved the road to how we currently understand the complex organization of this large family into protein networks. The goal of this chapter is to provide an overview of chaperome networks in cancer cells, with a focus on two cellular states defined by chaperome network organization.
Armada
发表于 2025-3-27 13:56:13
http://reply.papertrans.cn/43/4204/420330/420330_35.png
Obstreperous
发表于 2025-3-27 19:41:10
The Impact of the ER Unfolded Protein Response on Cancer Initiation and Progression: Therapeutic Imphe unfolded protein response (UPR). This adaptive response is mediated by the transmembrane signal transducers IRE1, PERK, and ATF6 to decide cell fate of recovery or death. In malignant cells, UPR signalling may be required to maintain ER homeostasis and survival in the tumor microenvironment chara
BAIT
发表于 2025-3-28 01:27:22
The Right Tool for the Job: An Overview of Hsp90 Inhibitorsns as well as the refolding of denatured proteins. While there are several classes of molecular chaperones in the cell, this chapter will focus solely on the small molecule modulation of Hsp90, the 90 kDa heat shock protein. Hsp90 is not only responsible for folding nascent proteins, but it also reg
MENT
发表于 2025-3-28 03:15:12
Lessons Learned from Proteasome Inhibitors, the Paradigm for Targeting Protein Homeostasis in Cancericult to bring to clinical practice, with one major exception: proteasome inhibition. These small molecules have dramatically transformed outcomes for patients with the blood cancer multiple myeloma. However, these agents have failed to make an impact in more common solid tumors. Major questions rem
Mast-Cell
发表于 2025-3-28 10:02:18
http://reply.papertrans.cn/43/4204/420330/420330_39.png
四溢
发表于 2025-3-28 11:42:29
http://reply.papertrans.cn/43/4204/420330/420330_40.png